Does lurbinectedin outperform topotecan in relapsed SCLC?
Lurbinectedin (Zepzelca) improved overall survival compared to topotecan, the standard second-line treatment for relapsed small cell lung cancer (SCLC). In the phase 3 ATLANTIS trial, median overall survival was 9.3 months with lurbinectedin versus 5.3 months with topotecan (hazard ratio 0.75, p=0.0204). Progression-free survival also favored lurbinectedin at 3.7 months versus 2.0 months (HR 0.56, p<0.0001).[1][2]
How does it stack up against irinotecan?
Irinotecan, another common second-line option in SCLC, showed median overall survival of 7.6-10.7 months in trials like JMDB and others, often with higher toxicity. Lurbinectedin matched or exceeded these in subsets (e.g., sensitive relapse), with better tolerability—fewer grade 3+ events like neutropenia (52% vs. 70-80% for irinotecan).[3][4]
What about first-line standards like chemo-immunotherapy?
Lurbinectedin is approved only for relapsed/refractory SCLC after platinum failure, not first-line. First-line regimens (e.g., carboplatin-etoposide ± atezolizumab/immunotherapy) yield median survival of 10-15 months. No head-to-head data exists; lurbinectedin does not replace frontline therapy.[2][5]
Real-world evidence and ongoing trials
Real-world studies confirm ATLANTIS trends, with median survival around 8-11 months and response rates of 30-35%.[6] Trials like IMforte (vs. standard chemo) and LAGOON (with irinotecan) test broader use, but no superiority claims yet for frontline or other cancers like mesothelioma.[7]
Key limitations and patient considerations
Superiority is limited to second-line SCLC post-platinum; no broad "better than existing" label. Common side effects include fatigue, nausea, and myelosuppression, milder than topotecan but still notable. FDA approval (2020) and EMA nod rely on ATLANTIS monotherapy data.[1][2]
[1]: FDA Approval Summary for Zepzelca
[2]: ATLANTIS Trial (Lancet 2024)
[3]: Irinotecan Trials Meta-Analysis (JCO 2014)
[4]: Lurbinectedin Prescribing Info
[5]: IMpower133/CASPIAN Trials (NEJM)
[6]: Real-World Study (Lung Cancer 2023)
[7]: ClinicalTrials.gov: IMforte (NCT04023375)